340450.KQ GC Genome Corporation Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
03:10
19 авг
19 авг
GC Genome expects Japan and US approvals.
GC Genome holds the #1 market share in Korea's NIPT market, generating continuous quarterly profits and holding over 40 billion KRW in net cash. Upcoming catalysts include Japan MHLW certification in September and US FDA submission for its pancreatic cancer screening test.
Выс.
02:21
19 авг
19 авг
GC Genome has liquid biopsy catalysts
GC Genome is Korea's NIFTY prenatal screening leader with an estimated 35% market share, profitable operations, and a strong cash position relative to its market cap. Catalysts include possible Japan Ministry of Health approval in September, US colorectal cancer screening clinical results by September-October and potential FDA submission in December. Global peers Guardant Health and Natera show the market opportunity, and Stanley Druckenmiller has a large position in Natera.
Выс.
Об аналитическом покрытии 340450.KQ
Buzzberg отслеживает 340450.KQ (GC Genome Corporation) в 1 источниках. Бычьих сигналов: 1, медвежьих: 0, от 1 аналитиков. Сентимент преимущественно бычий (50%). Всего отслеживаются 2 торговые идеи. За последние 7 дней: бычьих: 1, наблюдение: 1. Последние спикеры: Noh Young-rae.